Potent anticancer drug isolated from weedJuly 10th, 2012 - 1:01 pm ICT by IANS
Washington, July 10 (IANS) Scientists have isolated a potent anticancer compound from a Mediterranean weed that acts like ‘molecular grenade’.
In lab studies, researchers said they found that a three-day course of the drug called G202 reduced the size of human prostate tumours grown in mice by an average of 50 percent within 30 days.
G202 outdid the chemotherapy drug docetaxel, reducing seven of nine human prostate tumours in mice by more than 50 percent in 21 days. Docetaxel reduced one of eight human prostate tumours in mice by more than 50 percent in the same time period, the journal Science Translational Medicine reports.
Researchers from the Johns Hopkins Kimmel Cancer Centre and Denmark also reported that G202 produced at least 50 percent regression in models of human breast cancer, kidney cancer and bladder cancer, according to a Johns Hopkins statement
Based on these results, Johns Hopkins physicians have performed a phase I clinical trial to assess safety of the drug and have thus far treated 29 patients with advanced cancer. Besides, the University of Wisconsin and the University of Texas San Antonio are participating in the trial. A phase II trial to test the drug in patients with prostate cancer and liver cancer is planned.
The drug G202 is chemically derived from a weed called Thapsia garganica that grows naturally in the Mediterranean region. The plant makes a product, dubbed thapsigargin, that since the time of ancient Greece has been known to be toxic to animals.
“Our goal was to try to re-engineer this very toxic natural plant product into a drug we might use to treat human cancer,” says Samuel Denmeade, professor of oncology, urology, pharmacology and molecular sciences, who led the study. “We achieved this by creating a format that requires modification by cells to release the active drug.”
The drug can be injected and can travel through the bloodstream until it finds the site of cancer cells and hits a protein called prostate-specific membrane antigen (PSMA).
PSMA is released by cells lining tumours of the prostate and other areas, and in effect “pulls the pin” on G202, releasing cell killing agents into the tumour and the blood vessels that feed it, as well as to other cells in the vicinity.
- Heart drug cuts prostate cancer risk - Apr 03, 2011
- Iranian scientist creates gas-filled aspirin to fight cancer - Mar 13, 2012
- Cardiac drug, digoxin, could lower risk for prostate cancer - Apr 04, 2011
- Magnets help fight prostate cancer - Nov 09, 2011
- Super vaccine could knock out 70 percent of cancers - Dec 13, 2011
- Scientists unveil prostate cancer 'homing device' for drug delivery - Jul 07, 2009
- Asian mushrooms could help fight prostate cancer - May 24, 2011
- Slowing down prostate cancer by starving its cells - Nov 03, 2011
- Electric shocks soften up cancer cells for treatment - Dec 07, 2010
- Cholesterol drug could treat prostate cancer - Sep 21, 2010
- Soya beans could help to fight cancer - Jan 14, 2011
- Beehive extract may arrest prostate cancer - May 06, 2012
- New aspirin curbs 11 kinds of cancer, shrinks tumours - Mar 09, 2012
- Combo therapy may overcome Herceptin-resistant breast cancer - Mar 14, 2011
- 'Longevity' protein may ward off precursor to prostate cancer - Jan 14, 2011
Tags: ancient greece, anticancer compound, anticancer drug, bladder cancer, breast cancer, cancer cells, cancer centre, chemotherapy drug, docetaxel, hopkins physicians, human breast cancer, human cancer, journal science, kidney cancer, kimmel cancer, liver cancer, molecular sciences, same time period, translational medicine, university of texas san antonio